Mediware Acquisition Gains Market Momentum by Adding Major New Customer

LENEXA, Kan., July 17, 2012 (GLOBE NEWSWIRE) -- Mediware Information Systems, Inc. (MEDW) announced today that the global cord blood therapeutic company, Stemcyte, has licensed the Transtem cell therapy software to automate manufacturing processes associated with the company's cord blood collection and storage business. The Transtem software provides automated controls to streamline collection, testing and manufacturing processes for cord blood and adult stem cell products used in the treatment of cancer, blood diseases and research. Mediware announced the acquisition of Transtem on January 4, 2012 as part of its strategy to expand its focus from blood management to cellular therapy. A webcast featuring the Transtem capabilities for cord blood collection and processing is scheduled for July 18 and July 31 at 10 a.m. CDT (register online).

With operations in the United States, India and Taiwan, Stemcyte has more than 50,000 cord blood units in its public and private inventories and is in the process of applying for licensure with the United States Food and Drug Administration (USFDA). The company is planning to leverage Transtem to improve donor recruitment and institute new controls in the company's manufacturing processes, both of which are needed to support their plans for efficient growth and expansion.

The Transtem software is unique in that it provides comprehensive support for cell therapy and cord blood operations, with specialized functionality that spans from online donor registration through product collection, preparation, storage, infusion and outcome reporting. The software has robust laboratory and clinical capabilities which operate as an integrated suite to span from donor to patient outcome for organizations managing the full continuum of care.

Specific to Stemcyte's needs, the Transtem software has powerful online donor registration capabilities that will enable Stemcyte to more effectively recruit and enlist new donors through web based forms and eligibility checks. This functionality alone provides cord blood banks the opportunity to significantly boost collections and growth.

Other key Transtem capabilities important to cord blood banks include:

Mediware's expansion into cellular therapy technologies continues the company's nearly 40 year legacy of providing leading edge blood management technologies. These include the first transfusion management software system cleared for use by the U.S. Food and Drug Administration in hospital blood banks, as well as donor recruitment and laboratory software solutions used by major blood centers.

The company is hosting two informational webcasts to illustrate how the Transtem software solves the unique challenges that private and public cord blood banks face worldwide. The programs are scheduled for July 18 and July 31, at 10 am CDT. Online registration for either date is required and is available from Mediware's online event center (http://mediware.webex.com).

Additional information about the full range of software capabilities is available online or by emailing info@mediware.com.

About Mediware

Mediware delivers interoperable best-of-breed software systems that improve efficiencies and address safety concerns, enabling healthcare organizations to improve care processes while decreasing costs. Core Mediware solutions include blood management technologies for hospitals and blood centers; cell therapy solutions for cord blood banks, cancer treatment centers and research facilities; medication management solutions for hospitals, behavioral health facilities, infusion and specialty pharmacy providers; and business intelligence-based performance management solutions for clinical, regulatory and financial aspects of the broader healthcare market. For more information about Mediware products and services, visit our website at http://www.mediware.com.

Excerpt from:
Mediware Acquisition Gains Market Momentum by Adding Major New Customer